1.27.2010

2010 first Risk Sharing deal with NICE

National Institute for Health and Clinical Excellence

January 2010

Final appraisal determination
Certolizumab pegol for the treatment of rheumatoid arthritis

1 Guidance
1.1 Certolizumab pegol is recommended as an option for the treatment of people with rheumatoid arthritis only if:
certolizumab pegol is used as described for other tumour necrosis factor (TNF)-inhibitor treatments in ‘Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis’ (NICE technology appraisal guidance 130) and
the manufacturer provides the first 12 weeks of certolizumab pegol (10 pre-loaded 200-mg syringes) free of charge to all patients starting treatment.

This is an approximate $4,000 reduction from the first year access cost of Cimzia.

4 comments:

Anonymous said...

In today's company internal regular meeting, we had an introduction presentation about patient access schemes(PAS). Interesting topic but I am wondering how public reimbursement authorities in UK,Canada, Australia, US etc response to increasing use of PAS in the traditional cost effectiveness analysis(CEA). Is the result from PAS-incorporated CEA more appropriate than without-PAS CEA in terms of demosntrating economic value of study products? Will the decision made according to such analysis cause ethic issue? Or, is the PAS just used as a marketing tool for pharmaceutical companies? its future is more about negotiation tool for pharma with payers?

salisbury said...

Can someone please explain to me how giving away the first 12-weeks of product qualifies as "risk-share"?

ustaginnus@hotmail.com said...

salisbury.. you are absolutely right, that is a discount, nothing else

ustaginnus@hotmail.com said...

as for the anonymous comment, many PAS are a result of not meeting the CE criteria in the first place.. also, when you need to create further evidence of product value they are a good measure to obtain market access in order to continue to develop data and conduct than an ex post assessment.. so marketing tool is not the right terminology